Drug Trial Radar · NCT03417687
Hyperpolarized Xenon MRI for Assessment of Pulmonary Function in Lung Resection
Last checked: Nov 19, 2026Latest source record: Jun 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
Aug 17, 2018
Primary completion
Oct 31, 2019
Study completion Mar 10, 2020
Sponsor
- Lead sponsor
- Polarean, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 31, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study compares the equivalence of hyperpolarized 129Xe MRI as compared to 133Xe scintigraphy for the evaluation of pulmonary function in patients being evaluated for lung resection.
Conditions
- Pulmonary Surgical Procedures
Interventions
129Xe MRIDrug
Evaluation of pulmonary function
133 Xe scintigraphyDrug
Evaluation of pulmonary function
Primary outcomes
What the sponsor says the trial is designed to measure.
- Predicted Percentage of Remaining Pulmonary FunctionTime frame: 48 hours
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Duke University Hospital
Durham, North Carolina
University of Cincinnati Medical Center
Cincinnati, Ohio
University of Virginia
Charlottesville, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.